RECRUITING

Prostate Cancer Diagnosis by Multiparametric Ultrasound (Wholemount)

Description

This phase III trial investigates if perflutren lipid microspheres with ultrasound can be used to diagnose prostate cancer non-invasively. Definity (perflutren lipid microspheres) is an ultrasound contrast agent that is typically used for ultrasound bubble studies that involve the heart. Definity appears on ultrasound images as tiny gas-filled microbubbles. These microbubbles are about the size of a red blood cell and do not stay in a patient's body for more than several minutes, where they are excreted from the lungs and exhaled back into the air when breathing. Definity may enhance ultrasound images of the prostate and help doctors identify prostate cancer on ultrasound images.

Study Overview

Study Details

Study overview

This phase III trial investigates if perflutren lipid microspheres with ultrasound can be used to diagnose prostate cancer non-invasively. Definity (perflutren lipid microspheres) is an ultrasound contrast agent that is typically used for ultrasound bubble studies that involve the heart. Definity appears on ultrasound images as tiny gas-filled microbubbles. These microbubbles are about the size of a red blood cell and do not stay in a patient's body for more than several minutes, where they are excreted from the lungs and exhaled back into the air when breathing. Definity may enhance ultrasound images of the prostate and help doctors identify prostate cancer on ultrasound images.

Prostate Cancer Diagnosis by Multiparametric Ultrasound (Wholemount)

Prostate Cancer Diagnosis by Multiparametric Ultrasound (Wholemount)

Condition
Prostate Carcinoma
Intervention / Treatment

-

Contacts and Locations

Philadelphia

Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States, 19107

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Subject must be scheduled for radical prostatectomy for treatment of prostate cancer
  • * Subject must be able and willing to give written informed consent for a contrast enhanced ultrasound study of the prostate prior to prostatectomy
  • * Subject must be a male at least 18 years of age when informed consent is obtained
  • * Participant in a clinical trial involving an investigational drug within the past 30 days
  • * Patients with known or suspected hypersensitivity to perflutren, PEG, or any other component of Definity
  • * Previous treatment for prostate cancer, including hormone therapy
  • * Clinically unstable, severely ill, or moribund as per treating physician

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

MALE

Accepts Healthy Volunteers

No

Collaborators and Investigators

Thomas Jefferson University,

Study Record Dates

2026-05-26